Non-executive directors

Andy McKeon

Vice Chair of NICE

Andy McKeon has been a Non-executive director at NICE since 2009. He joined the Department of Health in 1976 after graduating from Cambridge University. He became a departmental board member as Director General of Policy and Planning in 2002 with oversight of the Department of Health's policy agenda for the reform and improvement of health and social care. His post also covered all aspects of pharmaceuticals and pharmacy and the clinical and cost effective use of medicines in the NHS.

Between 2003 and 2012 Andy was a managing director at the Audit Commission, responsible for all the Commission's work in the NHS and on health matters and for general management of the Commission's field force. Andy is currently an adjunct professor at the Institute of Global Health Innovation at Imperial College and a Non-executive Director of EMIS. He is a former trustee of the Nuffield Trust and is now interim chief executive.


Professor Martin Cowie

Non-Executive Director

Professor Martin Cowie is Professor of Cardiology at Imperial College and an Honorary Consultant Cardiologist at the Royal Brompton and Harefield NHS Foundation Trust.

Since 2003 he has been a clinical advisor for NICE on our acute and chronic heart failure guidelines, quality standards, commissioning guides, patient decision aids, and technology appraisals. In 2012 he became a NICE Specialty Advisor for cardiovascular interventions.

His major clinical and research interests are in health technology assessment and the delivery of efficient and effective care for patients with heart failure, focusing on new technologies: diagnostics, drugs or devices


Angela Coulter

Non-Executive Director

Professor Angela Coulter is a health policy analyst and researcher, with special interests in patient and public involvement. Her previous roles include Chief Executive of Picker Institute Europe, Director of Policy and Development at the King’s Fund, Director of the Health Services Research Unit at the University of Oxford and Director of Global Initiatives at the Informed Medical Decisions Foundation.

Angela has published more than 300 research papers and reports. She is the author of several books including The European Patient of the Future, winner of the 2004 Baxter Award. Her work has received awards from the Donabedian Foundation of Barcelona in 2012 and the International Shared Decision Making Conference in 2013.


Tom Wright

Non-Executive Director

Tom Wright CBE is Chief Executive of Age UK and is also chair of the Richmond Group of 14 leading health charities. Tom also sits on a range of health and social care bodies such as the Global Council on Brain Health.


Professor Sheena Asthana

Non-Executive Director

Professor Sheena Asthana is Professor of Health Policy at the University of Plymouth. Her research and teaching focus is on inequalities in health and health care, international public health and evidence-based public health.

She has worked with NICE to produce systematic reviews, evidence synthesis and economic analyses to inform our public health programme. Sheena brings experience of a wide variety of board appointments.


Dr Rosie Benneyworth

Non-Executive Director

Dr Benneyworth is currently the Managing Director of the South West Academic Health Science Network (AHSN). She has spent many years as a GP principal in Somerset and she currently works for Somerset Doctors Urgent Care Service.

Prior to joining the AHSN, Rosie worked for several years as a clinical commissioner. She was on the Governing Body of Somerset CCG and was the vice-chair of Somerset Health and Wellbeing Board.

Dr Benneyworth has also been a NICE Fellow since 2013, and was a member of the group that developed the NICE guideline on Urinary Incontinence in Women.


Tim Irish

Non-Executive Director

Tim Irish has worked for 30 years in the healthcare industry, both in the UK and internationally.

From 2012 to 2015, he was Chairman of the Board of Directors of Nexstim plc - a medical technology company focusing on improving rehabilitation for stroke patients. He has worked at a senior level in international companies which produce medical products. He was global head of marketing and strategy for Phillips Medical and a Vice President for GE Medical in Europe.

Before joining the Board at NICE, Tim held a number of non-executive roles at Board level in technology businesses.


Elaine Inglesby-Burke

Non-Executive Director

Elaine Inglesby-Burke has been a registered nurse since 1980. Her previous roles include being a nurse specialist manager at St Helens and Knowsley Hospital Trust and Director of Nursing at The Walton Centre in Liverpool. Most recently, Elaine was appointed Deputy Chief Executive at Salford Royal NHS Foundation Trust. She is also on the governing body at St Helens Clinical Commissioning Group and Willowbrook Hospice in St Helens.

Elaine has also played a significant role in national health campaigns, having been a member of the Prime Minister’s Nursing and Care Quality Forum. She was also involved with the Berwick National Advisory Group on the Safety of Patients in England, which is a group of healthcare experts that was set up to examine patient safety issues in the NHS.

Last year, Elaine was awarded a CBE on the Queen’s Birthday Honours List for her services to nursing.


Dr Rima Makarem

Non-Executive Director

Dr Rima Makarem has been Audit Chair in several NHS organisations, recently at NHS London and now at University College London Hospital. She is also the Chair for the National Travel Health Network and Centre (NaTHNaC), an Independent Council Member at St George’s University of London and a Board Trustee at Anchor Trust, a leading national provider of care homes and sheltered accommodation.

Rima has previously worked in the pharmaceutical industry in a number of roles including Director of Competitive Excellence at GlaxoSmithKline.


Industry representatives

Uday Bose

Industry representative

Uday Bose is currently Corporate Vice President, Head of Global Marketing, for Boehringer Ingelheim, Oncology. Based in Germany, he is responsible for all commercial aspects for the oncology portfolio spanning early development through to their marketed compounds.

Uday has extensive experience of the industry gained over 20 years. He started in health economics and has worked on NICE submissions and negotiations from his previous industry roles. The vast majority of his experience is with specialty products in oncology, osteoporosis and diseases of the CNS. In addition, he serves as Chair of Governors for his local infant and nursery school in West London.


Dr Mark Chakravarty

Industry representative

Mark holds a degree in Pharmacology and qualified in Medicine at the University of Manchester, UK, in 1995. He then held various hospital appointments in clinical medicine before taking a joint Medical Adviser post with the NHS Executive in the North West.

During this time Mark was the Chairman of the Northwest Junior Doctors Committee, executive member of the National Junior Doctors Committee of the British Medical Association, and a national negotiator for Junior Doctors. He then studied business at Manchester Business School before joining Procter & Gamble, in 1999, as a Medical Advisor for Cardiology.

Mark held various roles in Procter & Gamble from 1999 – 2017, including Head of Global Communications for Baby, Feminine & Family Care. Mark is currently the Global Head of Communications and Patient Relations for Novartis Pharma.


Dr Mercia Page

Industry representative

Dr Page qualified in medicine from Kings College Hospital Medical School and spent 8 years in hospital practice in the NHS, before joining the pharmaceutical industry. She gained experience in clinical research and specialised in pharmaceutical medicine. She also completed an MBA from Ashridge in 2001.

Dr Page joined NICE in autumn 2003 as the Associate Director for the Guidelines Programme, and became the Director of the Centre for Clinical Practice. Mercia was a Director of Medical Affairs at MSD Ltd between April 2008 and March 2016. She was appointed to SMC as an industry member between 2009 and 2012. She is now a consultant pharmaceutical physician.


Dr David Gillen

Industry representative

Dr David Gillen (BSc MD FFPM) has been a member of the Appeal Committee since 2012. He is Medical Director for Celgene UK and Ireland. Prior to this role he was Head of International Medical Affairs for Gilead Sciences where he managed and led a group of Medical Directors across Europe and Asia-Pacific. Before this he was Vice President Medical Affairs for the Pfizer Primary Care Business Unit covering Europe, Canada, Australia and New Zealand where he established a regional medical affairs group covering Pfizer's primary care portfolio of medicines.

David qualified in Medicine from St Mary's Hospital in 1992. During his undergraduate medical training he completed a BSc in Physiology and Clinical Pharmacology. He retained this interest in Pharmaceutical Medicine during his postgraduate training in Medicine, Cardiology and General Practice and joined Pfizer Global Research and Development in Sandwich in 1998. At Pfizer, David has worked in R&D and in Medical Affairs for the UK and in New York for 4 years. David is passionate about and active in the UK Clinical Research community, most recently being part of the Academy of Medical Sciences working group looking into Streamlining UK Clinical Research Governance.

Beyond clinical research, David has served on the Innovation Sub-committee of the ABPI (Initiating the ABPI Real - World data project), has worked at NICE and the UKCRC and was a member of the RCP working party looking at the relationship between industry, academic medicine and the NHS.


Patrick Hopkinson

Industry representative

Patrick is Director of Market Access and External Affairs at Bristol Myers Squibb. In his role Patrick leads the key market access functions including Government Affairs, Communications, Pricing , Pharmacy & Distribution and Health Economics and Outcomes Research.

He manages the strategic and operational interfaces with UK HTA bodies (ie NICE, SMC and AWMSG), the NHS, Department of Health and Government. He represents BMS on a number of Industry bodies including the ABPI Value and Uptake Group and the American Pharmaceutical Group. He Chairs the ABPI Pharmaceutical Stroke Prevention in Atrial Fibrillation Initiative. Previously he was involved in a number of key Life Science policy initiatives including the ABPI/DoH Joint Working Task Force, the Office of Life Science Blue Print and the QIPP National Initiative.

Patrick joined BMS in Sept 2010. Previously he had spent 14 years at GSK in a variety of roles. He joined as a health economist in R&D, moved rapidly to a global strategic marketing role before moving to GSK UK. Following roles in sales management and marketing he was appointed Business Unit Director for the Specialist portfolio and finally appointed Director Portfolio and Partnership Marketing a key strategic department pioneering innovative projects with the NHS.

Prior to GSK, Patrick worked as a Clinical Pharmacist for 8 years specialising in Oncology and Palliative Care. Initially at Guys and St Thomas' London and then Royal Berkshire Hospital Reading. He holds a Diploma in Clinical Pharmacy, a Masters in Health Economics and a MBA from Henley Management School


Stuart Carroll

Industry representative

Stuart is a senior health economist and market access expert specialising in pharmaceuticals, health technology appraisal (HTA) and health policy. He holds a BA (Hons) in Politics and Economics (1st Class) from the University of Northumbria at Newcastle, an MSc in Health Economics (Distinction) from the University of York, and an MBA (Distinction) from the Imperial Business School. Stuart is currently the Head of Value & Access for Sanofi Pasteur (a company specialising in vaccines) and a member of the leadership team for UK & Ireland.

Prior to this, he was the Head of Market Access for UK & Ireland Biogen Idec in the UK & Ireland (a biotechnology company specialising in multiple sclerosis) having previously been the Head of Health Economics & Epidemiology in the UK for Sanofi Pasteur MSD (a leading pharmaceutical company specialising in vaccines) and having worked as a health economics consultant and policy adviser specialising in HTA, pricing and reimbursement and local market access pathways in the NHS.

Stuart has over 12 years of experience leading and managing multiple HTAs including for the National Institute for Health and Care Excellence (NICE), the Scottish Medicines Consortium (SMC), the All Wales Medicines Strategy Group (AWMSG) and the National Centre for Pharmacoeconomics (NCPE). As part of these HTA submissions, Stuart has been responsible for overseeing patient access schemes and the implementation of pricing agreements. He has also led and managed HTA and pricing submissions in Australia, New Zealand, Canada, Germany, France, Italy, Spain, Portugal, Sweden, Denmark, Norway, Finland and Eastern Europe, and has experience in leading national tenders for UK-wide vaccination programmes and liaising with the Joint Committee on Vaccination and Immunisation (JCVI). Stuart is a Fellow of the Royal Society of Public Health, a member of the New Drugs Committee (NDC) for the Scottish Medicines Consortium (SMC), and a Local Councillor for the Royal Borough of Windsor & Maidenhead where he is the Cabinet Member for Public Health & Communications.


David Tyas

Industry representative

David is the Associate Director for Health Economics and Outcomes Research (HEOR) at Bristol-Myers Squbb (BMS) UK & Ireland. David leads the BMS HEOR team and oversees all health economic activities and is accountable for ensuring scientifically robust evidence submission dossiers are prepared for all UK and Irish Health Technology Appraisal bodies.

David has been active in Health Technology Appraisals for over 10 years and previously held positions with other Association of the British Pharmaceutical Industry (ABPI) member companies: Lundbeck, Novartis, and AstraZeneca.

David currently represents BMS at ABPI for HTA related work streams and previously was a member of the NICE topic selection panel for mental health and a health economist industry representative on the New Medicines Group for the AWMSG.

David holds a PhD in Neurobiology from the University of Edinburgh and a Postgraduate diploma in Health Economics from the University of York.


Lay representatives

Dr Jonathan Fear

Lay representative and appeal panel chair

Dr Fear is an experienced Consultant in Public Health Medicine having provided senior public health leadership in a variety of organisations and settings, including Board level responsibility as Director of Public Health for Leeds West Primary Care Trust. Most recently he was Head of Health Care Effectiveness and Deputy Director of Public Health for NHS Leeds. At the end of 2012 he retired from the NHS but continued to chair the Leeds Clinical Commissioning Groups' Individual Funding Request panels on a consultancy basis and provide Leeds Clinical Commissioning Groups with advice on policy development.

Between 2002 and 2006 he was Director of Public Health at Leeds West PCT, responsible for the recruitment and development of a team of 34 staff (100 including Prison Healthcare staff) and accountable for a budget of about £25 million.

In his last NHS role he provided public health leadership to the planned urgent screening and specialist services integrated commissioning team for NHS Leeds and was the public health lead for one of the GP consortia and NHS Leeds corporate leadership team. He was Deputy Director of Public Health and public health lead and board member for Leeds South and East Clinical Commissioning Group.

He was a member of NICE Technical Appraisal Committee D for 3 years and chaired the IFR panels in Leeds since 2006.


John Morris

Lay representative

John Morris has been a member of the Appeal Committee since 2011. Dr Morris's career began in pharmaceutical and crop protection scientific research. During this time he also developed an interest and expertise in psychodynamic counselling and interpersonal skills training. He then took these varied experiences and skills to the voluntary sector, managing information, support and advocacy services in two health charities, covering haemophilia and thrombosis and associated conditions such as hepatitis C and HIV.

Membership of another charity's advisory panel, the Long-term Medical Conditions Alliance and Patients in NICE gave him a broader understanding of the needs of people living with medical conditions. Having twice been a patient expert on hepatitis C NICE technology appraisals, he then joined the Royal College of Physicians to project manage the development of NICE clinical guidelines, primarily working on the COPD update. Most recently, he applied his ability of ‘translating' complex medical information into lay language to writing training materials on a host of healthcare subjects, and continues to support the UK's first gene therapy trial for haemophilia as its patient ombudsman.

He is passionate about empowering people to be self-managers of their health conditions and to participate fully in locally and national decision-making about NHS service provision. In particular, he is committed to ensuring the patient/carer voice is heard at all stages of the TA process.


Nikhil Gokani

Lay representative

Nikhil is a researcher at the School of Law and Social Justice, at the University of Liverpool, where he is also the Deputy Director of the Law and Non-Communicable Diseases (NCD) Unit. His work looks at improving public health through the prevention of non-communicable diseases – particularly obesity, type 2 diabetes, cardiovascular diseases, chronic pulmonary diseases and cancers.

Nikhil is a regular presenter at national and international conferences. As part of his advisory and consultancy work, he works with national governments across the world, international bodies, charities and national groups. He also teaches university students.

Nikhil sits on a number of committees. These have included committees at NICE, three committees at the Royal College of Physicians, NHS Health and Social Care Information Centre, National Institute for Health Research, and the National Clinical Guideline Centre. Nikhil has also been a charity trustee, a governor, and has past board-level experience in commercial healthcare. He is also a Fellow of the Royal Society for Public Health.


Professor Alan Silman

Lay representative and appeal panel chair

Alan is responsible for providing the strategic direction and leadership to our research and education activities. He has been involved in medical research in the musculoskeletal field for the past 30 years, and prior to joining Arthritis Research UK was Director of the (then) arc's Epidemiology Unit (1988-2006). Until the end of 2011 Alan was a consultant rheumatologist at the Manchester Royal Infirmary.

Some of his milestones include leading the Epidemiology Unit to its award as the European League Against Rheumatism (EULAR) Centre of Excellence in 2006; he was Heberden Orator in 2004; he received Honorary Doctorates from UEA in 2009 and Keele University in 2012. Alan is the UK editor of the main leading international textbook ‘Rheumatology' and is a distinguished speaker both in the UK and overseas.

His external responsibilities include membership of the MHRA Pharmacovigilance Expert Advisory Group; Chairman of the Assessment Panels of UK Universities Research Assessment Exercise (2002-2008); and Chairman, Ministry of Defence panel of research into the health of servicemen and women. He chaired the NICE panel on local formularies 2012 and convened a round table workshop with NICE in 2009 to identify how Arthritis Research UK as a research organisation could work with NICE both to enhance quality of evidence base for the TA's as well as follow up when there are NICE research recommendations.


Colin Standfield

Lay representative

Colin Standfield has been a member of the Appeal Committee since 2011. Colin is an Oxford MA in English and has a background at Board level in advertising and marketing. He also has a long association with substance misuse issues and worked for 10 years as a Trustee and then Development Officer with Battling Addictions Together, a user-led Ealing charity helping people recover from drug and alcohol problems. He is a Trustee of Drugscope and has been involved with a number of Ealing and pan-London committees in the field, including the Ealing Drug and Alcohol Task Group and the Greater London Alcohol and Drug Alliance. He is Church Council Secretary and a former Senior Steward at Hanwell Methodist Church.

He is a skilled presenter and has experience of service improvement within the NHS; he has run redesign programmes for Substance Misuse and Mental Health teams in boroughs across the country. Colin was the elected Chair of the Ealing and West London Research Ethics Committee for over four years and was a Non-Executive Director of Ealing Primary Care Trust from 2004 to 2007.


Paddy Storrie

Patient representative and appeal panel chair

Paddy Storrie is a history teacher and has been involved as a lay member with NICE since 2004, initially for four years as a member of the Citizens' Council, and since 2009 as a lay member on Appraisals Committee D. He sat in 2010-11 on the Academy of Medical Science Working Group on the Regulation and Governance of Medical Research. Paddy is a member of the MHRA Patient and Public Engagement Expert Advisory Group. He is on the Steering Committee of the High Intensity Specialist Led Acute Care research project, and has spoken twice at the Forum of Health Technology Appraisal International, a clearing house made up of representatives of regulators, payer bodies, and health technology businesses.


NHS representatives

Dr Marios Adamou

NHS representative

Marios Adamou is a Consultant Psychiatrist in neurodevelopmental psychiatry (ADHD and ASD) at South West Yorkshire Partnership NHS Foundation Trust. He is the Head of Specialist Service Development and Foundation Trust Governor at the same organisation. He is a board member of the Governing body of East Ridings Clinical Commissioning Group. He holds offices at the Royal College of Psychiatrists where he is a member (MRCPsych). He is presently the Deputy Regional Advisor for the Yorkshire Region, elected member of the Executive Committee of the Faculty of General Adult Psychiatry whose is the policy lead, and co-opted member for the Northern and Yorkshire Division.

His Medical Training (MD) was completed at the Aristotle University, Thessaloniki, Greece and his Psychiatric training at Guys, Kings and St Thomas's scheme in London. He held full time research positions at the University of Kent and Institute of Psychiatry, London.

Marios has academic qualifications in a number of disciplines. He completed postgraduate degrees (MSc) in Mental Health Studies, MA (History), LL.M (Medical Law), MBA (Business Administration) and PGCE (Medical Education). He earned a postgraduate diploma in Occupational Medicine (DOccMed) awarded by the Faculty of Occupational Medicine of the Royal College of Physicians. He completed a PhD by research.

He is an International Fellow at the Centre for Innovation in Health Management at the University of Leeds and Executive Committee Member at the UK adult ADHD Network (UKAAN). He is the Chair of the Northern Adult ADHD Clinician's Group (NACG).

He is a Fellow of the Higher Education Academy (FHEA), the Royal Society of Arts (FRSA), the Royal Society of Public Health (FRSPH) and the Society of Biology (FSB). He is a founding member of the Faculty of Medical Leadership and Management. He is a Chartered Member of the Chartered Management Institute (CMgr MCMI).


Dr Frank McKenna BA MD FRCP

NHS representative and appeal panel chair

Frank McKenna has been a member of the Appeal Committee since 2008. Dr McKenna is a Consultant Physician and Rheumatologist at Trafford General Hospital in Manchester and Honorary Clinical Lecturer at the University of Manchester. He also examines for the MRCP (UK).

He has had a lengthy contribution to medical management and has undertaken a number of roles including latterly that of operational medical director. He has a prolonged interest in clinical pharmacology of anti-rheumatic drug therapy. His active research interests are currently in biologic drug therapy and the role of sleep pathology in rheumatic diseases. He has represented the British Society for Rheumatology on several NICE appraisals for the treatment of rheumatoid arthritis and is treasurer for the BSR.


Dr Anthony Emmerson BSc MD FRCP FRCPCH

NHS representative

Consultant Neonatologist, St Mary's Hospital, Central Manchester University Hospitals NHS Foundation Trust.

Dr Anthony Emmerson has been a consultant neonatologist since 1993. In the recent past, as Clinical Lead for the Neonatal Network and Medical Director of the Neonatal Intensive Care Partnership, he was instrumental in delivering the Making it Better reconfiguration of obstetric, neonatal and paediatric services across Greater Manchester. He has sat on the NICE Interventional Procedures Advisory Committee since 2012 and was involved with developing the quality standards for Hypertension in Pregnancy. He is a clinical advisor for the Parliamentary and Health Service Ombudsman.

He has had a long standing interest in medical education and is Head of School of Paediatrics in the North Western Deanery. He has experience of appeals panels relating to training issues. He has research interests in neonatal care including vitamin D levels in newborn infants and is Medical Editor of the Journal Infant.


Kevin O'Shaughnessy

NHS representative

Kevin O’Shaughnessy has been a Consultant Clinical Pharmacologist since 1995. He studied Pharmacology before completing his medical training in Oxford with post-graduate training at the Hammersmith Hospital London.

He is currently an honorary Consultant Physician at Addenbrookes Hospital, Cambridge and a Reader in Clinical Pharmacology at the University of Cambridge. He also undertakes basic research into hypertension and has an active role in clinical pharmacology training for the East of England.


Dr Biba Stanton BMedSci (Hons) MBBS (Hons) MRCP PhD

NHS representative

Specialist registrar in Neurology at the Royal Free Hospital

Dr Biba Stanton is a specialist registrar in neurology at the Royal Free Hospital, with a clinical interest in behavioural neurology and functional disorders. She graduated in medicine from the University of Newcastle-Upon-Tyne in 2000 with distinction, having also been awarded first class honours in her intercalated Bachelor of Medical Science degree.

She was awarded a PhD in psychology from King’s College London in 2009, and has research experience in epidemiology, clinical trials, neuropsychology and neuro-imaging. She chaired the Association of British Neurologists (ABN) trainees’ committee from 2009-2013, also serving on ABN Council, the ABN meetings committee, the Joint Clinical Neurosciences committee of the Royal College of Physicians and the neurology Specialty Advisory Committee. She works part time, spending two days per week looking after her 3 young sons, and is also a Governor of Rosendale Primary School.


Dr Ashutosh Wechalekar MD, FRCP, FRCPath, DM,

NHS representative

UK National Amyloidosis Centre, Department of Medicine, University College London Medical School, Royal Free Campus, London, UK

Ashutosh Wechalekar is a Senior Lecturer and Honorary Consultant Haematologist at University College London Medical School and the Royal Free London NHS Foundation Trust.

He trained in haematology in the UK and Canada. In 2004, he joined the UK National Amyloidosis Centre funded by a grant from Leukaemia research fund and is a consultant at the centre since 2007. He is a board member of UK Myeloma forum. He has been key in establishing the UK amyloidosis network and represents the network as a stakeholder in various forums. He is a member of the British Society haematology guidelines group for developing guidelines for treatment of multiple myeloma and AL amyloidosis.

His clinical research has clarified the role of drugs like bortezomib in the treatment pathway for amyloidosis. His academic interests are focused on biomarkers in cardiac amyloidosis, novel imaging methods for the heart in all types of amyloidosis, characterization and treatment of systemic AL amyloidosis as well as multiple myeloma including clinical trials of new and novel agents in these disorders. He has published extensively in these areas.